YAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a ...
YAVNE, Israel, Feb. 12, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair today announced the results of ...
A large-scale, real-world analysis of 15,639 patients treated with Collagenase SANTYL Ointment underscores the clinical and economic benefits of early enzymatic debridement in wound management. Using ...
Recent research is revealing key insights about the therapeutic potential of clostridial collagenase. Join us for this upcoming webinar to learn about new data on SANTYL® ointment’s unique mechanisms ...
MediWound Ltd. announced the publication of a peer-reviewed post hoc analysis in the journal Wounds, based on data from its Phase II ChronEx clinical trial for patients with venous leg ulcers (VLUs).
FORT WORTH, Texas and PETERBOROUGH, Ontario, Jan. 26 Healthpoint today announced that it will begin marketing Collagenase SANTYL® Ointment to healthcare professionals in Canada. SANTYL® Ointment is a ...
FORT WORTH, Texas, April 4 /PRNewswire/-- HEALTHPOINT, Ltd., a DFB Pharmaceuticals Inc. affiliate company, today announced that it will begin marketing and selling the Collagenase SANTYL(R) Ointment ...
Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL® “These new findings are consistent with my ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback